Tumor microenvironmental cytokines bound to cancer exosomes determine uptake by cytokine receptor-expressing cells and biodistribution.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
10 06 2021
Historique:
received: 22 07 2020
accepted: 26 05 2021
entrez: 11 6 2021
pubmed: 12 6 2021
medline: 30 6 2021
Statut: epublish

Résumé

Metastatic spread of a cancer to secondary sites is a coordinated, non-random process. Cancer cell-secreted vesicles, especially exosomes, have recently been implicated in the guidance of metastatic dissemination, with specific surface composition determining some aspects of organ-specific localization. Nevertheless, whether the tumor microenvironment influences exosome biodistribution has yet to be investigated. Here, we show that microenvironmental cytokines, particularly CCL2, decorate cancer exosomes via binding to surface glycosaminoglycan side chains of proteoglycans, causing exosome accumulation in specific cell subsets and organs. Exosome retention results in changes in the immune landscape within these organs, coupled with a higher metastatic burden. Strikingly, CCL2-decorated exosomes are directed to a subset of cells that express the CCL2 receptor CCR2, demonstrating that exosome-bound cytokines are a crucial determinant of exosome-cell interactions. In addition to the finding that cytokine-conjugated exosomes are detected in the blood of cancer patients, we discovered that healthy subjects derived exosomes are also associated with cytokines. Although displaying a different profile from exosomes isolated from cancer patients, it further indicates that specific combinations of cytokines bound to exosomes could likewise affect other physiological and disease settings.

Identifiants

pubmed: 34112803
doi: 10.1038/s41467-021-23946-8
pii: 10.1038/s41467-021-23946-8
pmc: PMC8192925
doi:

Substances chimiques

CCL2 protein, human 0
CCR2 protein, human 0
Chemokine CCL2 0
Cytokines 0
Glycosaminoglycans 0
Proteoglycans 0
Receptors, CCR2 0
Receptors, Cytokine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3543

Références

PLoS One. 2010 Jul 22;5(7):e11469
pubmed: 20661468
Biochemistry. 1997 Nov 4;36(44):13570-8
pubmed: 9354625
Cancer Res. 2012 Apr 1;72(7):1694-704
pubmed: 22354750
Proteomics. 2017 Dec;17(23-24):
pubmed: 28722786
Nat Rev Cancer. 2006 Jun;6(6):449-58
pubmed: 16723991
Cancer Immunol Res. 2018 Sep;6(9):1046-1056
pubmed: 30002156
Proteomics. 2019 Apr;19(8):e1800180
pubmed: 30672117
Cancer Res. 2012 Aug 15;72(16):3906-11
pubmed: 22751463
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Semin Cell Dev Biol. 2017 Jul;67:3-10
pubmed: 28077297
Cancer Res. 2016 Dec 1;76(23):6816-6827
pubmed: 27760789
Sci Rep. 2018 Jun 12;8(1):8973
pubmed: 29895824
Biochemistry. 1999 Sep 28;38(39):12959-68
pubmed: 10504268
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1885-90
pubmed: 12571364
Gastroenterology. 2015 Jul;149(1):201-10
pubmed: 25888329
ACS Nano. 2020 May 26;14(5):5435-5444
pubmed: 32286793
ACS Sens. 2018 Dec 28;3(12):2637-2643
pubmed: 30381940
Clin Cancer Res. 2003 Nov 1;9(14):5113-9
pubmed: 14613988
Cancer Metastasis Rev. 2013 Dec;32(3-4):449-64
pubmed: 23636348
Cancer Res. 2019 Jun 15;79(12):3011-3027
pubmed: 31053634
Proteomics. 2017 Dec;17(23-24):
pubmed: 29115712
Front Immunol. 2019 Apr 24;10:875
pubmed: 31068944
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
Anal Chem. 2017 Jun 20;89(12):6695-6701
pubmed: 28541032
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Oncogene. 2009 Jan 15;28(2):289-96
pubmed: 18850011
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
J Extracell Vesicles. 2015 Jul 17;4:27031
pubmed: 26194179
Cell Mol Life Sci. 2011 Aug;68(16):2667-88
pubmed: 21560073
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905

Auteurs

Luize G Lima (LG)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Sunyoung Ham (S)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.

Hyunku Shin (H)

Department of Bio-convergence Engineering, Korea University, Seoul, South Korea.

Edna P Z Chai (EPZ)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.

Erica S H Lek (ESH)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
School of Chemistry and Molecular Biosciences, Faculty of Science, University of Queensland, Brisbane, QLD, Australia.

Richard J Lobb (RJ)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD, Australia.

Alexandra F Müller (AF)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Suresh Mathivanan (S)

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.

Belinda Yeo (B)

Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Melbourne, VIC, Australia.

Yeonho Choi (Y)

Department of Bio-convergence Engineering, Korea University, Seoul, South Korea.
School of Biomedical Engineering, Korea University, Seoul, South Korea.
Department of Bioengineering, Korea University, Seoul, South Korea.

Belinda S Parker (BS)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.

Andreas Möller (A)

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. andreas.moller@qimrberghofer.edu.au.
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. andreas.moller@qimrberghofer.edu.au.
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. andreas.moller@qimrberghofer.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH